• The first report of a treatment that can improve survival among COVID-19 patients on ventilators or oxygen comes from the RECOVERY trial; researchers announce that a low-dose of the steroid dexamethasone, which is inexpensive and widely available, reduced deaths among people on ventilators by one-third, and by one-fifth among people who were receiving oxygen, demonstrating a “…clear and large…” survival benefit. Sources 1,2
• Pre-clinical studies of the hepatitis C virus (HCV) direct-acting antivirals (HCV), sofosbuvir (SOF) and daclatasvir (DCV), report activity against SARS-CoV-2 – especially for daclatasvir. A 14-day treatment course of SOF/DCV could be profitably mass-produced for $5.00. Sources 1,2
